Judges Scientific plc (LSE:JDG) featured among the day's top gainers on 26 August 2026, the shares adding 2.53% to 4,050p and valuing the group at roughly £263.1m. The modest rise, however, sits awkwardly against a much harsher backdrop: Judges, long celebrated as one of AIM's premier serial acquirers of niche scientific-instrument businesses, has seen its shares more than halve from past highs above £90. The company buys and builds specialist manufacturers serving universities, industry and regulators, funding deals largely with Debt and compounding returns over the long run. That model has not broken, but a squeeze on order intake, US research-funding uncertainty and the absence of a lucrative oceanographic contract have forced a painful re-rating that a single day's bounce does little to reverse.
What Happened to Judges Scientific Shares?
Tuesday's 2.53% advance to 4,050p was not tied to any fresh company announcement; no regulatory news was released on the day, and the move most plausibly reflects broader small-cap sentiment ahead of interim results due on 23 September 2026. There is, in short, no single verified catalyst behind the gain.
The far more important story is the de-rating. Judges traded above £90 at its peak, having compounded Shareholder value for well over a decade, and has since lost more than half its value. The unwind reflects genuine deterioration rather than mere sentiment: organic order intake weakened through 2025 and into 2026, the US market that historically supplies about a quarter of Revenue contracted sharply, and a high-margin Geotek coring expedition that had flattered prior comparatives dropped out of the numbers. A share once priced for serene, uninterrupted compounding was repriced for cyclicality.
Latest Company Developments
In its half-year trading update on 23 July 2026, Judges disclosed that first-half revenue fell 21% to £49.14m, from £70.2m in the same period of 2025. The steep drop was heavily distorted by the absence of a Geotek coring expedition; stripping that out, Rest of World revenue actually grew 9%. Management guided to first-half adjusted Earnings Per Share of 38p to 42p and reaffirmed that full-year 2026 results should land in line with market expectations, framed around 202.8p of adjusted basic EPS.
Encouragingly, the order picture showed signs of stabilising. Organic order intake fell 11% year on year, but the weakness was concentrated in the first quarter, with second-quarter intake described as broadly in line with the prior year. The order book stood at 17.3 weeks, up from 15.7 weeks at the 2025 year-end and roughly level with the 17.4 weeks a year earlier. Less welcome was confirmation that the next Geotek coring expedition, previously pencilled in for early 2027, will now be scheduled no earlier than 2028, removing a potential earnings Kicker from next year's outlook.
Financial Performance
The 2025 full-year figures, published on 31 March 2026, capture the pressures. Revenue rose 9.1% to £145.8m (2024: £133.6m), but adjusted operating profit was essentially flat at £28.0m (2024: £27.9m) and adjusted pre-tax profit edged up to £24.4m (2024: £24.3m). Statutory pre-tax profit fell to £8.9m from £13.0m, weighed down by acquisition-related Amortisation and finance costs. Adjusted EPS came in at 275.3p.
Order intake told the underlying tale: on a like-for-like basis, excluding Geotek's coring work, organic orders fell 6%. Sales to the USA declined 22% organically, with order intake there down 23%, as Washington's moves to restrict federal funding of scientific research bit hard. China and Hong Kong, by contrast, recovered, with order intake up 8%.
On the balance sheet, adjusted net debt improved to £42.6m from £51.7m a year earlier, aided by strong cash conversion and a quiet year for acquisitions. The board lifted the total Dividend 10% to 115p, including an 82.3p final, signalling continued confidence in cash generation despite the trading squeeze.
The Growth Story
The Investment case rests on acquisition-led compounding. Judges owns 24 subsidiaries, including Armfield, CoolLED, Geotek, Quorum Technologies and Teer Coatings, each a specialist in instruments used across higher education, Manufacturing and regulatory testing. Historically, the group has deployed debt to acquire cash-generative niche businesses at disciplined multiples, then let their profits and its own low Cost of Capital do the compounding. Underpinning Demand is the long-term global expansion of higher education and scientific research, plus continued corporate and regulatory appetite for measurement, coating and analysis technology.
Deal flow, though, has slowed. Beyond an 18% minority stake in Geotek do Brasil for £1.9m cash plus an earn-out capped at £0.7m, 2025 brought no major acquisitions; the group's most recent sizeable deals, including Teer Coatings, Luciol and Rockwash, were completed in 2024. Management attributed the lull to a climate in which cash-rich owners are reluctant to sell. A recovery in order intake and a return of deal activity are the twin levers that could reignite the growth engine.
Risks Investors Should Watch
The clearest risk is cyclicality in academic and government research budgets, which US federal-funding uncertainty has thrown into sharp relief; management cautioned that even with Congress restoring funds, it is unclear when money will flow. Concentration in the US, at roughly a quarter of revenue, amplifies that exposure, while China and other markets add their own volatility. The debt-funded Acquisition model, so powerful in the ascent, cuts both ways when organic profits stall, and integration of a growing Subsidiary base is never risk-free. Finally, even after the sharp de-rating, a quality compounder can carry a valuation that leaves little Margin for further disappointment.
What Could Drive the Shares Next?
The 23 September 2026 interim results are the near-term focus, offering confirmation of the 38p–42p adjusted EPS guide, an updated net-debt figure and, crucially, fresh commentary on order momentum. A durable turn in organic order intake, a genuine thaw in US research funding, or a return to acquisitions on attractive terms would each strengthen the case for a recovery. Conversely, further slippage in orders or the coring timetable would test patience.
The Bottom Line
Judges Scientific (LSE:JDG) remains a well-run, cash-generative compounder whose long-term model looks intact, but the past two years have been a reminder that even quality serial acquirers are not immune to end-market cycles. The fall from highs above £90 reflects real headwinds: soft US demand, a 6% organic order decline in 2025 and the loss of a high-margin oceanographic contract. Set against that, the group has trimmed net debt to £42.6m, raised its dividend 10% and seen order intake steady through the second quarter. Whether Tuesday's 2.53% gain marks a genuine inflection or merely noise depends on the September interims and the pace of any recovery in orders and acquisitions. This article is for information only and is not investment advice.




_11_18_2026_14_55_02_703826.jpg)

Please wait processing your request...